Evaluating only CohBar’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
MILESTONE
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
CohBar developed mitochondria-based therapeutics targeting metabolic diseases, NASH, and aging. The company raised $56M and had scientifically interesting work but faced significant challenges translating preclinical data into human trials. After years of failing to secure partnership deals or advance to proof-of-concept, CohBar filed to dissolve voluntarily in February 2023.
Lesson
“Deep biology platforms need to demonstrate a minimum viable clinical signal in at least one indication before the capital markets close.”